期刊文献+

Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis 被引量:12

Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis
下载PDF
导出
摘要 AIM: To clarify whether there is any difference in the symptom relief in patients with reflux esophagitis following the administration of four Proton pump inhibitors (PPIs). METHODS: Two hundred and seventy-four patients with erosive reflux esophagitis were randomized to receive 8 wk of 20 mg omeprazole (n = 68), 30 mg of lansoprazole (n = 69), 40 mg of pantoprazole (n = 69), 40 mg of esomeprazole (n = 68) once a day in the morning. Daily changes in heartburn and acid reflux symptoms in the first 7 d of administration were assessed using a six-point scale (0: none; 1: mild; 2: mild-moderate; 3: moderate; 4: moderate-severe; 5: severe). RESULTS: The mean heartburn score in patients treated with esomeprazole more rapidly decreased than those receiving other PPI. Complete resolution of heartburn was also more rapid in patients treated with esomeprazole for 5 d compared with omeprazole (P = 0.0018, P = 0.0098, P = 0.0027, P = 0.0137, P = 0.0069, respectively), lansoprazole (P = 0.0020, P = 0.0046, P = 0.0037, P = 0.0016, P = 0.0076, respectively), and pantoprazole (P = 0.0006, P = 0.0005, P = 0.0009, P = 0.0031, P = 0.0119, respectively). There were no significant differences between the four groups in the rate of endoscopic healing of reflux esophagitis at week 8. CONCLUSION: Esomeprazole may be more effective than omeprazole, lansoprazole, and pantoprazole for the rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis. AIM: To clarify whether there is any difference in the symptom relief in patients with reflux esophagitis following the administration of four Proton pump inhibitors (PPIs). METHODS: Two hundred and seventy-four patients with erosive reflux esophagitis were randomized to receive 8 wk of 20 mg omeprazole (n = 68), 30 mg of lansoprazole (n = 69), 40 mg of pantoprazole (n = 69), 40 mg of esomeprazole (n = 68) once a day in the morning. Daily changes in heartburn and acid reflux symptoms in the first 7 d of administration were assessed using a six-point scale (0: none; 1: mild; 2: mild-moderate; 3: moderate; 4: moderate-severe; 5: severe). RESULTS: The mean heartburn score in patients treated with esomeprazole more rapidly decreased than those receiving other PPI. Complete resolution of heartburn was also more rapid in patients treated with esomeprazole for 5 d compared with omeprazole (P = 0.0018, P = 0.0098, P = 0.0027, P = 0.0137, P = 0.0069, respectively), lansoprazole (P = 0.0020, P = 0.0046, P = 0.0037, P = 0.0016, P = 0.0076, respectively), and pantoprazole (P = 0.0006, P = 0.0005, P = 0.0009, P = 0.0031, P = 0.0119, respectively). There were no significant differences between the four groups in the rate of endoscopic healing of reflux esophagitis at week 8. CONCLUSION: Esomeprazole may be more effective than omeprazole, lansoprazole, and pantoprazole for the rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis.
作者 Ri-Nan Zheng
机构地区 Hainan Medical College
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第8期990-995,共6页 世界胃肠病学杂志(英文版)
关键词 OMEPRAZOLE PANTOPRAZOLE LANSOPRAZOLE ESOMEPRAZOLE Reflux esophagitis Symptom relief 返流性食管炎 埃索美拉唑比 奥美拉唑 兰索拉唑 泮托拉唑 症状 减轻 质子泵抑制剂
  • 相关文献

参考文献32

  • 1Kennedy T,Jones R.The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms.Aliment Pharmacol Ther 2000; 14:1589-1594
  • 2Locke GR 3rd,Talley NJ,Fett SL,Zinsmeister AR,Melton LJ 3rd.Prevalence and clinical spectrum of gastroesophageal reflux:a population-based study in Olmsted County,Minnesota.Gastroenterology 1997; 112:1448-1456
  • 3Shaw MJ,Talley NJ,Beebe TJ,Rockwood T,Carlsson R,Adlis S,Fendrick AM,Jones R,Dent J,Bytzer P.Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease.Am J Gastroenterol 2001; 96:52-57
  • 4Spechler SJ.Epidemiology and natural history of gastrooesophageal reflux disease.Digestion 1992; 51 Suppl 1:24-29
  • 5Orlando RC.The pathogenesis of gastroesophageal reflux disease:the relationship between epithelial defense,dysmotility,and acid exposure.Am J Gastroenterol 1997; 92:3S-5S; discussion 5S-7S
  • 6Johnston BT,Collins JS,McFarland RJ,Love AH.Are esophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn.Am J Gastroenterol 1994; 89:497-502
  • 7Winters C Jr,Spurling TJ,Chobanian SJ,Curtis DJ,Esposito RL,Hacker JF 3rd,Johnson DA,Cruess DF,Cotelingam JD,Gurney MS.Barrett's esophagus.A prevalent,occult complication of gastroesophageal reflux disease.Gastroenterology 1987; 92:118-124
  • 8Holloway RH,Dent J,Narielvala F,Mackinnon AM.Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.Gut 1996; 38:649-654
  • 9Johansson KE,Ask P,Boeryd B,Fransson SG,Tibbling L.Oesophagitis,signs of reflux,and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease.Scand J Gastroenterol 1986; 21:837-847
  • 10Bell NJ,Hunt RH.Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.Gut 1992; 33:118-124

同被引文献118

引证文献12

二级引证文献212

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部